Structure Therapeutics (GPCR) Stock Jumps 10% After Breakthrough GLP-1 Weight Loss Data

TLDR

• Aleniglipron, Structure Therapeutics’ oral GLP-1 candidate, achieved 16.3% placebo-adjusted weight reduction after 44 weeks in the ACCESS II Phase 2 study
• Data surpassed oral GLP-1 competitors from Eli Lilly (12.4%) and Novo Nordisk (13.6%) in comparable Phase 2 studies
• Continuous weight reduction with no plateau observed, distinguishing it from competing therapies
• Structure Therapeutics stock climbed approximately 10% Monday, reaching $59.80 following the announcement
• FDA end-of-Phase 2 consultation scheduled for Q2 2026, with Phase 3 trials commencing in H2 2026

Structure Therapeutics delivered impressive Phase 2 results for aleniglipron, its oral GLP-1 obesity treatment, on Monday morning, propelling GPCR shares up roughly 10% during early market hours.

Structure Therapeutics Inc., GPCR

The ACCESS II clinical trial demonstrated placebo-adjusted weight reduction of 16.3% with the 180 mg dosage and 16.0% with the 240 mg dosage following 44 weeks of treatment. Importantly, neither dosage exhibited signs of weight loss plateauing.

These outcomes favorably compare against competing oral GLP-1 therapies. Novo Nordisk’s oral version of Wegovy achieved 13.6% weight reduction in Phase 3 trials. Meanwhile, Eli Lilly’s orforglipron candidate delivered approximately 12.4% in Phase 2 studies and 11.2% in Phase 3.

Previous data released in December had demonstrated 14.2% weight loss with a reduced dosage. Participants maintaining that lower dosage for 53 weeks ultimately achieved 16% weight reduction, suggesting sustained therapeutic benefits over extended treatment periods.

The safety and tolerability profile remained favorable. Within the ACCESS Open Label Extension trial, only 2% of participants discontinued due to adverse events. The body composition substudy reported a 3.4% discontinuation rate. Structure’s strategy of initiating treatment at a conservative 2.5 mg dose appears instrumental in supporting patient adherence.

These positive results have sparked acquisition speculation within the investment community. H.C. Wainwright’s analyst Ananda Ghosh previously identified aleniglipron this month as “the most acquirable asset in obesity.” The investment firm elevated its price target to $114. Citizens maintained its Market Outperform rating while adjusting its target downward to $113.

Analyst Reactions

Leerink Partners confirmed its Outperform rating alongside a $90 price target following the data release. The firm emphasized the favorable tolerability characteristics and dose-dependent response as particularly encouraging findings.

RBC Capital Markets adopted a more cautious perspective. Analyst Trung Huynh observed that orforglipron demonstrated comparable Phase 2 performance before delivering weaker Phase 3 results. He identified an atypically minimal weight gain among placebo participants as a potential statistical anomaly deserving scrutiny. RBC maintained its Outperform rating on Lilly with a $1,250 price target.

What Comes Next

Structure Therapeutics has scheduled an end-of-Phase 2 consultation with the FDA during Q2 2026. Phase 3 clinical trials are anticipated to launch during the second half of 2026. Data from both high-dose cohorts in Phase 2 will determine which dosage advances into late-stage development.

Despite Monday’s rally, the stock remains down 23% year-to-date entering the trading session, although it has surged 155% over the trailing twelve months. Trading at $59.80, GPCR shares sit considerably below Wall Street’s consensus price targets, which span from $90 to $140.

Cantor Fitzgerald had previously identified this 44-week data readout as a significant catalyst for the stock. That prediction materialized accurately.

Monday’s price appreciation elevated GPCR’s market capitalization to roughly $3.81 billion.

The post Structure Therapeutics (GPCR) Stock Jumps 10% After Breakthrough GLP-1 Weight Loss Data appeared first on Blockonomi.